RECOVER-ENERGIZE 平台协议_附录 B(结构化起搏 (PEM))
RECOVER-ENERGIZE:评估 SARS-CoV-2 感染急性后遗症运动不耐受干预措施的平台方案 (PASC)
This is a platform protocol designed to be flexible so that it is suitable for a range of interventions and settings within diverse health care systems and community settings with incorporation into clinical COVID-19 management programs and treatment plans if results achieve key study outcomes.
This protocol is a prospective, multi-center, multi-arm, randomized, controlled platform trial evaluating interventions to address and improve exercise intolerance and post-exertional malaise (PEM) as manifestations of Post-Acute Sequelae of SARS-CoV-2 Infection (PASC).
The focus of this protocol is to assess interventions that can improve exercise capacity, daily activities tolerance, and quality of life in patients with PASC.
研究概览
详细说明
Study interventions will be added to the platform protocol as appendices. Each appendix will leverage all elements of the platform protocol, with additional elements described in the individual appendix. Study intervention appendices may be added or removed according to adaptive design and/or emerging evidence.
The platform protocol enrolls participants who meet study eligibility criteria. After completing initial screening assessments, eligible participants are assigned to one of the study intervention appendices that are actively enrolling. Participants must meet certain criteria within a specific appendix in order to be included in that appendix. Once assigned to an appendix, eligible participants are randomized to either the study intervention group or a control group.
研究类型
注册 (实际的)
阶段
- 不适用
联系人和位置
学习地点
-
-
North Carolina
-
Durham、North Carolina、美国、27710
- All sites listed under NCT06404047
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
• See NCT06404047 for RECOVER-ENERGIZE: Platform Protocol level inclusion and exclusion criteria which applies to this appendix
Additional Appendix B (Structured Pacing (PEM)) Level Inclusion Criteria:
- Participant identifies new PEM following a SARS-CoV-2 infection that has persisted for at least 12 weeks and is still present at the time of consent
- Score of 2 or greater for both frequency and severity for any of the first 5 questions on the Screening mDSQ-PEM AND Answer of YES to either item 7 or 8 on Screening mDSQ-PEM, and response of >14 h in item 9.
or Score of 3 or greater on any severity question(regardless) and answer of YES to either item 7 or 8 on the Screening mDSQ-PEM, and response of >14h in item 9.
Additional Appendix B (Structured Pacing (PEM)) Level Exclusion Criteria:
- Inability to attend in-person screening visit or participate in weekly visits (in-person [≥ 1] and remote)
- Participant was previously enrolled in Appendix A of this protocol and has NOT completed the full study follow-up period of Appendix A
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Structured Pacing (PEM)
Participants in this group will complete weekly pacing sessions for 12 weeks. Pacing sessions will last about 30 minutes, as tolerated. Each participant will meet with a provider 'pacing coach' who has received study-specific education about PEM and how to create and manage pacing strategies for participants. Sessions include PEM symptom and trigger assessment; task, function and activity analysis; adaptations and modifications. |
Participants in this group will complete weekly pacing sessions for 12 weeks. Pacing sessions will last about 30 minutes, as tolerated. Each participant will meet with a provider 'pacing coach' who has received study-specific education about PEM and how to create and manage pacing strategies for participants. Sessions include PEM symptom and trigger assessment; task, function and activity analysis; adaptations and modifications. |
|
其他:Usual Care
Participants in this group will receive basic education about PEM with a weekly call by site study staff for support and communication. |
Participants in this group will receive basic education about PEM with a weekly call by site study staff for support and communication. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in Frequency of PEM Symptoms, as Measured by the Modified DePaul Symptom - Post-Exertional Malaise Questionnaire (mDSQ-PEM)
大体时间:Baseline, week 12 (End Of Intervention, EOI)
|
Symptom frequency is rated on a 5-point Likert scale: 0 = none of the time, 1 = a little of the time, 2 = about half the time, 3 = most of the time, and 4 = all of the time. |
Baseline, week 12 (End Of Intervention, EOI)
|
|
Change in Severity of PEM Symptoms, as Measured by the Modified DePaul Symptom - Post-Exertional Malaise Questionnaire (mDSQ-PEM)
大体时间:Baseline, week 12 (EOI)
|
Symptom severity is rated on a 5-point Likert scale: 0 = symptom not present, 1 = mild, 2 = moderate, 3 = severe, 4 = very severe. |
Baseline, week 12 (EOI)
|
|
Change in Duration of PEM Symptoms, as Measured by the Modified DePaul Symptom - Post-Exertional Malaise Questionnaire (mDSQ-PEM)
大体时间:Baseline, week 12 (EOI)
|
Ordinal categorical response: <=1 hour, 2-3 hours, 4-10 hours, 11-13 hours, 14-23 hours, >=24 hours. Reported as the number of participants who provided each response. |
Baseline, week 12 (EOI)
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in PASC Symptoms, as Measured by the PROMIS-Cog Questionnaire
大体时间:Baseline, week 6 (Middle of Intervention), week 12 (EOI), month 6 (EOS)
|
The PROMIS Short Form v.2.0 - Cognitive Function 8a (PROMIS-Cog) is the PROMIS Short Form to assess cognitive function and is a self-report, 8-item questionnaire targeting cognitive function in the past seven days. T-Scores in a healthy reference population have mean=50 and standard deviation = 10, with higher scores indicating higher functioning. |
Baseline, week 6 (Middle of Intervention), week 12 (EOI), month 6 (EOS)
|
|
Change in Quality of Life, as Measured by the PROMIS-29+2
大体时间:Baseline, week 6 (Middle of Intervention), week 12 (EOI), month 6 (EOS)
|
The PROMIS-29+2 is used to calculate a preference score (PROPr) by the addition of two Cognitive Function Ability items. Preference-based scores provide an overall summary of health-related quality of life on a common metric. Preference-based scores summarize multiple domains on a metric ranging from 0 (as bad as dead) to 1 (perfect or ideal health). |
Baseline, week 6 (Middle of Intervention), week 12 (EOI), month 6 (EOS)
|
|
Change in Quality of Life, as Measured by the EQ-5D 5L
大体时间:Baseline, week 6 (Middle of Intervention), week 12 (EOI), month 6 (EOS)
|
The EQ-5D is a standardized measure of health status. Mobility was measured on a scale from 1 (no problems in walking) to 5 (unable to walk). |
Baseline, week 6 (Middle of Intervention), week 12 (EOI), month 6 (EOS)
|
|
Change in Step Count (Physical Activity) as Measured by Actigraphy
大体时间:Baseline, week 6 (Middle of Intervention), week 12 (EOI), month 6 (EOS)
|
Actigraphy will be measured by Fitbit. Participant steps were considered valid from days where they wore the Fitbit at least 10 waking hours. Average steps were calculated from subjects with at least 5 consecutive days of valid data within a week window of their expected visit dates. |
Baseline, week 6 (Middle of Intervention), week 12 (EOI), month 6 (EOS)
|
|
Change in Physical Activity, as Measured by the PROMIS SF-Physical Function (PROMIS-PF)
大体时间:Baseline, week 6 (Middle of Intervention), week 12 (EOI), month 6 (EOS)
|
The PROMIS Short Form v2.0 - Physical Function 8b (PROMIS-PF) consists of 8 items. The PROMIS Physical Function instruments measure self-reported capability rather than actual performance of physical activities. T-Scores in a healthy reference population have mean = 50 and standard deviation = 10, with higher scores indicating higher functioning. |
Baseline, week 6 (Middle of Intervention), week 12 (EOI), month 6 (EOS)
|
|
Change in Orthostatic Hypotension, as Measured by the Modified Orthostatic Hypotension Questionnaire (mOHQ)
大体时间:Screening, week 6 (Middle of Intervention), week 12 (EOI), month 6 (EOS)
|
The Orthostatic Hypotension Questionnaire (OHQ) is a measure of orthostatic intolerance. The modified OHQ (mOHQ) measure used in this study includes a total of ten items related to daily activities and symptoms. The OHQ composite score ranges from 0 (no burden) to 10 (maximal burden). Higher scores are worse. The OHQ composite score includes 6 symptom items (OISA) and 4 daily activity items (OIDAS). |
Screening, week 6 (Middle of Intervention), week 12 (EOI), month 6 (EOS)
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in PASC Symptoms, as Measured by the PASC Symptom Questionnaire
大体时间:Baseline, week 6 (Middle of Intervention), week 12 (EOI), month 6 (EOS)
|
The PASC Symptom Questionnaire is a 33-question survey for self-reporting multiple PASC-related symptoms across multiple systems. |
Baseline, week 6 (Middle of Intervention), week 12 (EOI), month 6 (EOS)
|
合作者和调查者
调查人员
- 学习椅:Gary M Felker, MD、Duke Clinical Research Institute
- 学习椅:Barry Make, MD、National Jewish Health
- 学习椅:Lucinda Bateman, MD、Bateman Horne Center
- 学习椅:Janna Friedly, MD, MPH、University of Washington
出版物和有用的链接
有用的网址
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
其他相关的 MeSH 术语
其他研究编号
- Pro00112409_B
- OT2HL156812 (美国 NIH 拨款/合同)
- NHLBI Grant to RTI (其他赠款/资助编号:RTI subcontracting with DCRI)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
The summary of the results will be shared on the study website: https://recovercovid.org/
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.